Kura Oncology forms Caspian Therapeutics, which raises USD 50 million in Series A financing
KURA•Series A financing and terms
Caspian raised USD 50 million in a Series A private financing on Sept. 8, 2026; Kura invested USD 4.3 million.
The deal includes cross-licenses, giving Caspian paid-up rights to certain ziftomenib patents for cardiometabolic use.
Kura will provide R&D and administrative services to Caspian under an intercompany services agreement with annual renewals.
Kura Oncology forms Caspian Therapeutics
Kura Oncology formed Caspian Therapeutics to develop next-generation menin inhibitors for diabetes and other cardiometabolic diseases.
Kura contributed rights to KO-7246 and related intellectual property to Caspian for common stock, retaining about 49.2% ownership.
Related News
Victoria's Secret & Co. <VSXY.N>: BMO Initiates Coverage With Market Perform Rating; Target Price $80
VSCO•
Robo.ai Announces Proposed Establishment Of Alif Maritec, A Marine Security And Intelligent Maritime Infrastructure Company
AIIO•
